Seeking AlphaCodex · 实盘不做把握 8/10
北京时间·🕒 发布 08-03 19:54:49时区推断·⟳ 抓取 08-03 19:54:51·⚡ 决策 08-04 09:42:58 +13h48m·84.7 天前
Curium拟以每股102.50美元现金加最高12美元CVR收购Lantheus
交易条款为每股102.50美元现金，另有最高12美元CVR，潜在总对价114.50美元，董事会已一致批准。
📄 原文Seeking Alpha↗ 原文
Curium to buy Lantheus for up to $114.50/share in cash
Curium announced a deal to acquire all outstanding Lantheus Holdings (LNTH) shares for up to $114.50 per share in cash,…
不做 Lantheus Holdings（LNTH.US）
同一并购催化已处理；现价101.19美元距102.50美元现金对价仅约1.3%，短线价差太薄且CVR不确定。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-08-03 · 扩散 high · price-in 风险 high ↗
消息传播链
- 报道Curium与Lantheus达成确定性合并协议，每股102.50美元现金加最高12美元CVR。市场反应:LNTH.US当日开盘102.66美元、收101.19美元，成交额和换手显著放大。
- 2026-08-04 00:05 UTC其它processed_events/twitter非一手已处理同一具体催化：BioCentury复盘放射性药物并购，Curium收购Lantheus。
关键理由
- 交易条款为每股102.50美元现金，另有最高12美元CVR，潜在总对价114.50美元，董事会已一致批准。
- LNTH.US最新价101.19美元，距确定现金对价102.50美元仅约1.3%，事件交易价差已经很薄；CVR到2030年商业里程碑不适合短线事件交易重仓估值。
- 同一Curium收购Lantheus催化已在08-04 00:05 UTC被已处理库记录，当前为重复转述。
主要风险
- 并购仍需监管和股东等交割条件，薄价差无法覆盖交易失败/时间成本风险。
反向证据
- 做多前查反向 · 来源 kb_search · 影响 weakens
内部KB未命中更早一手条款；但已处理库命中同一催化，且报价显示现金价差很薄。
检索:Lantheus Curium acquisition $102.50 $12 CVR August 2026
工具调用 · 历史记录,结果未知(4 种)
- stock_quote · 结果未知
- search_processed_events · 结果未知
- kb_search · 结果未知
- normalize_ticker · 结果未知
原文全文
展开原文 · 858 字
Curium announced a deal to acquire all outstanding Lantheus Holdings (LNTH) shares for up to $114.50 per share in cash, in a definitive agreement to merge with Lantheus.
Under the agreement, Lantheus shareholders will receive $102.50 per share in cash at closing, plus contingent value rights (CVRs) worth up to an additional $12.00 per share if certain commercial milestones are met through 2030, bringing the total potential consideration to $114.50 per share.
The offer represents a 38% premium to Lantheus' unaffected 60-day volume-weighted average share price as of May 21, 2026.
Together, Curium and Lantheus are positioned to create a radiopharmaceutical company spanning diagnostics and therapeutics, with the infrastructure and capabilities to serve patients in more than 70 countries. The board of Lantheus has unanimously approved the transaction.
Under the agreement, Lantheus shareholders will receive $102.50 per share in cash at closing, plus contingent value rights (CVRs) worth up to an additional $12.00 per share if certain commercial milestones are met through 2030, bringing the total potential consideration to $114.50 per share.
The offer represents a 38% premium to Lantheus' unaffected 60-day volume-weighted average share price as of May 21, 2026.
Together, Curium and Lantheus are positioned to create a radiopharmaceutical company spanning diagnostics and therapeutics, with the infrastructure and capabilities to serve patients in more than 70 countries. The board of Lantheus has unanimously approved the transaction.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。